Company Analysis
Sign in

Kura Oncology, Inc. (KURA)

Nasdaq: KURA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Full chart Alerts Compare
Grade5.9
◀ Past 7.3● Present 4.7▶ Future 6.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Kura Oncology, Inc.

Nine metrics read from its own filings, by tense
Headline grade
5.9/10
◀ Past7.330% of the headline
● Present4.740% of the headline
▶ Future6.230% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.3/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Kura Oncology, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.0/10

What has it actually done, year after year?

3 filed years; profitable in 0 of 3.

weight 45% of this tense · 70th percentile among 323 sector filers · read for its customers

From the record

Kura Oncology, Inc.'s 3 filed years say what it did: it rose in 1 of 1 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
6.6/10

How has it treated the people who own it?

SI estimate 6.6/10, confidence 35 of 100 (one part).

weight 22% of this tense · 66th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 34% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Kura Oncology, Inc.'s shareholder treatment is put at 6.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 34% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.7/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
3.9/10

Is it financially healthy right now?

ROE -160%: lost 160¢ per shareholder dollar. Leverage 76%: owes 76¢ per asset dollar.

weight 45% of this tense · 39th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Kura Oncology, Inc. lost about 160 cents for every dollar of shareholders' money. Leverage: it owed about 76 cents per dollar of assets, and net share issuance: its share count grew 1.8% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 19% of its family
  • return on equitybottom 20% of its family
  • the share count against the year beforetop 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
5.0/10

How strong is its position in its industry?

bottom 50% of 315 in its family; net margin -412.9%.

weight 33% of this tense · 50th percentile among 315 sector filers · read for its customers

From the record

Kura Oncology, Inc.'s standing among 315 graded names in its industry family: revenue of $67 million in fiscal 2025 ranks in the top 40% by size; a net margin of -412.9% ranks in the bottom 39% (its annual reports).

What it rests on

  • revenue against the family$67.5Mtop 40% of its family
  • net margin-412.9%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
5.9/10

What are the people in charge doing?

top 41% of 315 in its family for leadership; chief executive since 2015.

weight 22% of this tense · 59th percentile among 315 sector filers · read for its shareholders

From the record

Kura Oncology, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Wilson, Troy Edward (President and CEO, as filed), filing under that title since 2015-03-16, 11.7 years (top 12% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.3 years (bottom 41%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 49%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge7 in three years among 15 peoplebottom 49% of its family
  • the median years the people in charge have filed5.3 yearsbottom 41% of its family
  • the chief executive's years on the record11.7 yearstop 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

6.2/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
5.1/10

How much room does it have to grow?

top 49% of 273 in its family for room to expand.

weight 45% of this tense · 51st percentile among 273 sector filers · read for itself

From the record

Kura Oncology, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $149 million against debt of $10 million leaves 18.9% of its assets as net cash, bottom 37% of its family; cash from operations less capital spending is -104.8% of revenue (bottom 49%); research spending of 372.1% of revenue (top 33%) (its annual report).

What it rests on

  • cash less debt against assets18.9%bottom 37% of its family
  • cash from operations less capital spending against revenue-104.8%bottom 49% of its family
  • research spending against revenue372.1%top 33% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
8.3/10

What could actually drive growth from here?

top 17% of 306 in its family for growth drivers.

weight 33% of this tense · 83rd percentile among 306 sector filers · read for its customers

From the record

Kura Oncology, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 25.3% (top 34%); research spending grew 39.3% a year (top 11%); capital spending grew 119.7% a year (top 7%) (its annual reports). Kura Oncology, Inc. reported 2 product lines in fiscal 2025: License and Collaboration Revenue at $65 million (97%), Product at $2 million (3%); 1 of 1 grew against the year before (its annual report).

What it rests on

  • the newest year's revenue growth25.3%top 34% of its family
  • three-year growth of research spending39.3%top 11% of its family
  • three-year growth of capital spending119.7%top 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 234 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Kura Oncology, Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton KURA · research, not advice